Lansoprazole is a benzimidazole which specifically inhibits the H+/K+ ATP-ase (proton pump) of the parietal cells in the gastric mucosa.
Each capsule contains Lansoprazole U.S.P. 30 mg in delayed release form.
Healing and maintenance of duodenal ulcer, treatment of active benign gastric ulcer, healing of NSAIDs-associated gastric ulcer, risk reduction of NSAID-associated gastric ulcer, rhort term symptomatic treatment and maintenance of healing of gastro esophageal reflux disease(GERD), H. pylori eradication to reduce the risk of Duodenal Ulcer recurrence and for treatment of pathological hyper-secretory conditions like Zollinger Ellison syndrome.
DOSAGE & ADMINISTRATION:
Inhibitol should be taken once daily. To achieve the optimal acid inhibitory effect, and hence most rapid healing and symptom relief, lansoprazole should be administered in the morning before food. The capsules should be swallowed whole and not crushed or chewed. Duodenal ulcer: 30 mg daily for 4-8 weeks. Benign gastric ulcer: 30 mg daily for 8 weeks. Reflux esophagitis: 30 mg daily for 4-8 weeks, Zollinger Ellison syndrome: 60 mg daily to be continued till clinically indicated. Renal impairment: There is no need to alter the dosage in patients with impaired renal function. Hepatic impairment: The dose should not exceed 30 mg daily. Pregnancy: Inhibitol should be used only if clearly needed. Lactation: Animal studies indicate that lansoprazole is secreted into breast milk. However, breast-feeding should be discontinued if the use of lansoprazole is considered essential. Pediatric Use: The safety and effectiveness of lansoprazole in patients less than 1 year of age has not been established.
Hypersensitivity to lansoprazole.
A low incidence of adverse events has been reported including; headache, diarrhea, abdominal pain, dyspepsia, nausea, vomiting, dry mouth, constipation, flatulence, dizziness, fatigue, rash, urticaria and pruritis.
Inhibitol 30mg capsules: Blister pack of 1 x 14 capsules.